{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:21:10Z","timestamp":1790742070768,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The factors influencing long-term responses to a tumor necrosis factor inhibitor (TNFi) in rheumatoid arthritis (RA) patients currently remain unknown. Therefore, we herein conducted a multi-omics analysis of TNFi responses in a Japanese RA cohort. Blood samples were collected from 27 biological disease-modifying antirheumatic drug (DMARD)-naive RA patients at the initiation of and after three months of treatment with TNFi. Treatment responses were evaluated at one year. Differences in gene expression levels in peripheral blood mononuclear cells (PBMCs), plasma protein levels, drug concentrations, and the presence\/absence of anti-drug antibodies were investigated, and a cell phenotypic analysis of PBMCs was performed using flow cytometry. After one year of treatment, thirteen patients achieved clinical remission (responders), while the others did not or switched to other biologics (non-responders). Differentially expressed genes related to treatment responses were enriched for the interferon (IFN) pathway. The expression of type I IFN signaling-related genes was higher in non-responders than in responders before and after treatment (<jats:italic>P<\/jats:italic> = 0.03, 0.005, respectively). The expression of type II IFN signaling-related genes did not significantly differ before treatment; however, it increased in non-responders and decreased in responders, with a significant difference being observed after three months of treatment (<jats:italic>P<\/jats:italic> = 1.2\u00d710<jats:sup>-3<\/jats:sup>). The total number of lymphocytes and C-X-C Motif Chemokine Ligand 10 (CXCL10) protein levels were associated with the type I IFN signature (<jats:italic>P<\/jats:italic> = 6.7\u00d710<jats:sup>-7<\/jats:sup>, 6.4\u00d710<jats:sup>-3<\/jats:sup>, respectively). Hepatocyte growth factor (HGF) protein levels before treatment predicted fold increases in type II IFN (<jats:italic>P<\/jats:italic> = 0.03). These IFN signature-related indices (the number of lymphocytes, CXCL10, and HGF) significantly differed between responders and non-responders (<jats:italic>P<\/jats:italic> = 0.01, 0.01, and 0.04, respectively). A single-cell analysis revealed that the type I IFN signature was more highly enriched in monocytes than in other cell types. A deconvolution analysis of bulk-RNA sequence data identified CD4+ and CD8+ T cells as the main sources of the type II IFN signature in non-responders. Collectively, the present results demonstrated that the dynamics of the type I and II IFN pathways affected long-term responses to TNFi, providing information on its biological background and potential for clinical applications.<\/jats:p>","DOI":"10.3389\/fimmu.2022.901437","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T12:50:25Z","timestamp":1654519825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis"],"prefix":"10.3389","volume":"13","author":[{"given":"Takeshi","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Oku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yoshitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid Arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2017.26","article-title":"Systematic Review and Meta-Analysis: Pharmacogenetics of Anti-TNF Treatment Response in Rheumatoid Arthritis","volume":"17","author":"Bek","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","article-title":"Role of Cytokines in Rheumatoid Arthritis: An Education in Pathophysiology and Therapeutics","volume":"223","author":"Feldmann","year":"2008","journal-title":"Immunol Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab: Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10067-017-3639-0","article-title":"Application of Omics in Predicting Anti-TNF Efficacy in Rheumatoid Arthritis","volume":"37","author":"Xie","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/ar4504","article-title":"Lack of Validation of Genetic Variants Associated With Anti-Tumor Necrosis Factor Therapy Response in Rheumatoid Arthritis: A Genome-Wide Association Study Replication and Meta-Analysis","volume":"16","author":"M\u00e1rquez","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214877","article-title":"Association of Response to TNF Inhibitors in Rheumatoid Arthritis With Quantitative Trait Loci for CD40 and CD39","volume":"78","author":"Spiliopoulou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.41516","article-title":"Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis","volume":"73","author":"Tao","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-021-02451-9","article-title":"Transcriptome-Wide Study of TNF-Inhibitor Therapy in Rheumatoid Arthritis Reveals Early Signature of Successful Treatment","volume":"23","author":"OIiver","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e12760","DOI":"10.1111\/dth.12760","article-title":"Secondary Failure of TNF-\u03b1 Inhibitors in Clinical Practice","volume":"32","author":"Owczarczyk-Saczonek","year":"2019","journal-title":"Dermatol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEG354","article-title":"Ethnic Differences in Responses to Disease Modifying Drugs","volume":"42","author":"Helliwell","year":"2003","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059341","article-title":"Three Groups in the 28 Joints for Rheumatoid Arthritis Synovitis - Analysis Using More Than 17,000 Assessments in the KURAMA Database","volume":"8","author":"Terao","year":"2013","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ART.1780310302","article-title":"The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis","volume":"31","author":"Frank","year":"1988","journal-title":"Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461","article-title":"Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in Rheumatoid Arthritis: Agreement of the Disease Activity Score (DAS28) With the ARA Preliminary Remission Criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast Universal RNA-Seq Aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: Accurate Transcript Quantification From RNA-Seq Data With or Without a Reference Genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky955","article-title":"GENCODE Reference Annotation for the Human and Mouse Genomes","volume":"47","author":"Frankish","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0398-x","article-title":"The Immune Cell Landscape in Kidneys of Patients With Lupus Nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"eabd7600","DOI":"10.1126\/SCIADV.ABD7600","article-title":"Gene Expression Signatures of Target Tissues in Type 1 Diabetes, Lupus Erythematosus, Multiple Sclerosis, and Rheumatoid Arthritis","volume":"7","author":"Szymczak","year":"2021","journal-title":"Sci Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular Signatures Database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/J.CELL.2021.04.048","article-title":"Integrated Analysis of Multimodal Single-Cell Data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/S41587-019-0114-2","article-title":"Determining Cell Type Abundance and Expression From Bulk Tissues With Digital Cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/J.CELL.2021.03.056","article-title":"Dynamic Landscape of Immune Cell-Specific Gene Regulation in Immune-Mediated Diseases","volume":"184","author":"Ota","year":"2021","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and Loss of Response to TNF Inhibitors: Implications for Rheumatoid Arthritis Treatment","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.02007","article-title":"Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for its Use as a Clinical Biomarker","volume":"8","author":"Cava A","year":"2018","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1186\/ar3546","article-title":"Correlation of Antinuclear Antibody and Anti-Double-Stranded DNA Antibody With Clinical Response to Infliximab in Patients With Rheumatoid Arthritis: A Retrospective Clinical Study","volume":"13","author":"Yukawa","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu299","article-title":"Interferon Gene Expression Signature in Rheumatoid Arthritis Neutrophils Correlates With a Good Response to TNFi Therapy","volume":"54","author":"Wright","year":"2014","journal-title":"Rheumatol (United Kingdom)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5a0616-258r","article-title":"Neutrophil Biomarkers Predict Response to Therapy With Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis","volume":"101","author":"Wright","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)77222-0","article-title":"Identification of CRG-2. An Interferon-Inducible mRNA Predicted to Encode a Murine Monokine","volume":"265","author":"Vanguri","year":"1990","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13075-016-0920-6","article-title":"A Longitudinal Genome-Wide Association Study of Anti-Tumor Necrosis Factor Response Among Japanese Patients With Rheumatoid Arthritis","volume":"18","author":"Honne","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/ar3150","article-title":"Type I IFN and Tnf\u03b1 Cross-Regulation in Immune-Mediated Inflammatory Disease: Basic Concepts and Clinical Relevance","volume":"12","author":"Cantaert","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of Type-I- and Type-II-Interferon-Mediated Signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1053\/GAST.2002.34175","article-title":"Rapid Suppression of Hematopoiesis by Standard or Pegylated Interferon-Alpha","volume":"123","author":"PeckRadosavljevic","year":"2002","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ART.30573","article-title":"CXCL10 and its Receptor CXCR3 Regulate Synovial Fibroblast Invasion in Rheumatoid Arthritis","volume":"63","author":"Laragione","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/S13075-017-1353-6","article-title":"Pathogenic Roles of CXCL10 Signaling Through CXCR3 and TLR4 in Macrophages and T Cells: Relevance for Arthritis","volume":"19","author":"Lee","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jot.2020.10.011","article-title":"Hepatocyte Growth Factor Overexpression Promotes Osteoclastogenesis and Exacerbates Bone Loss in CIA Mice","volume":"27","author":"Huang","year":"2021","journal-title":"J Orthop Transl"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ART.30163","article-title":"Association Between High Plasma Levels of Hepatocyte Growth Factor and Progression of Radiographic Damage in the Joints of Patients With Rheumatoid Arthritis","volume":"63","author":"Grandaunet","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/S41584-019-0323-6","article-title":"Chemokines in Rheumatic Diseases: Pathogenic Role and Therapeutic Implications","volume":"15","author":"Miyabe","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/S41590-019-0378-1","article-title":"Defining Inflammatory Cell States in Rheumatoid Arthritis Joint Synovial Tissues by Integrating Single-Cell Transcriptomics and Mass Cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/S41577-018-0029-Z","article-title":"Ifn\u03b3: Signalling, Epigenetics and Roles in Immunity, Metabolism, Disease and Cancer Immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/315672A0","article-title":"Gamma-Interferon Transcriptionally Regulates an Early-Response Gene Containing Homology to Platelet Proteins","volume":"315","author":"Luster","year":"1985","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13075-019-1999-3","article-title":"Molecular Profiling of Rheumatoid Arthritis Patients Reveals an Association Between Innate and Adaptive Cell Populations and Response to Anti-Tumor Necrosis Factor","volume":"21","author":"Farutin","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13075-016-0995-0","article-title":"Baseline CXCL10 and CXCL13 Levels are Predictive Biomarkers for Tumor Necrosis Factor Inhibitor Therapy in Patients With Moderate to Severe Rheumatoid Arthritis: A Pilot, Prospective Study","volume":"18","author":"Han","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sdata.2018.15","article-title":"ImmPort, Toward Repurposing of Open Access Immunological Assay Data for Translational and Clinical Research","volume":"5","author":"Bhattacharya","year":"2018","journal-title":"Sci Data"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.901437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T12:50:29Z","timestamp":1654519829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.901437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.901437"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.901437","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"article-number":"901437"}}